In 2020, the Drug Enforcement Administration (DEA) began investigating PillPack for potential violations of the CSA, and in October of 2020 conducted an audit of PillPack, which revealed recordkeeping deficiencies. Specifically, DEA investigators found that PillPack’s records did not accurately reflect its inventory for ten Schedule III-V substances: Codeine #4, Tramadol, Zolpidem, Butalbital, Alprazolam, Acetaminophen with Codeine #3, Clonazepam, Lorazepam Carisoprodol, and Lyrica.